SEARCH

SEARCH BY CITATION

References

  • 1
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
  • 2
    Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827843.
  • 3
    Palella FJ, Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine 1998; 338: 853860.
  • 4
    UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Washington: UNAIDS, 2010.
  • 5
    Cockerham L, Scherzer R, Zolopa A et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010; 53: 102106.
  • 6
    Quiros-Roldan E, Torti C, Tinelli C et al. Risk factors for myocardial infarction in HIV-positive patients. Int J STD AIDS 2005; 16: 1418.
  • 7
    Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506512.
  • 8
    Aboud M, Elgalib A, Pomeroy L et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract 2010; 64: 12521259.
  • 9
    Barbaro G, Di Lorenzo G, Cirelli A et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25: 24052418.
  • 10
    Bedimo R , Westfall A , Drechsler H , Tebas P , editors. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, 2009 [Abstract MOAB202].
  • 11
    Benito R , Pinilla J , Labarga P et al., editors. Comparison of cardiovascular risk factors between HIV-infected patients and non-infected general population. The 14th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract B10290].
  • 12
    Bozzette SA, Ake CF, Tam HK et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47: 338341.
  • 13
    Coplan PM, Nikas A, Japour A et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003; 19: 449455.
  • 14
    Durand M , Sheehy O , Baril J-G , Lelorier J , Tremblay C , editors. Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID). 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, 2009 [Abstract TUPEB175].
  • 15
    Holmberg SD , Moorman AC , Tong TC et al., editors. Protease inhibitor drug use and adverse cardiovascular events in ambulatory HIV-infected patients. The 14th International AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeB4494].
  • 16
    Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV medicine 2005; 6: 3744.
  • 17
    Klein D , Hurley L , Silverberg M , Horberg M , Quesenberry C , Sidney S , editors. Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV- Northern Californians: 19942006. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, February 2007 [Abstract 807].
  • 18
    Kwong GP, Ghani AC, Rode RA et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20: 19411950.
  • 19
    Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24: 12281230.
  • 20
    Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 12281238.
  • 21
    Lichtenstein KA, Armon C, Buchacz K et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435447.
  • 22
    Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 23
    Obel N, Farkas DK, Kronborg G et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130136.
  • 24
    Obel N, Thomsen HF, Kronborg G et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44: 16251631.
  • 25
    Pere D, Ignacio SL, Ramon T et al. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J 2008; 2: 2638.
  • 26
    Phillips AN, Carr A, Neuhaus J et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177187.
  • 27
    Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 25062512.
  • 28
    Vaughn G, Detels R. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort. AIDS Care 2007; 19: 492499.
  • 29
    Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318330.
  • 30
    Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377384.
  • 31
    D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9: 15011515.
  • 32
    Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med 2009; 30: 213224.
  • 33
    Bohning D, Malzahn U, Dietz E, Schlattmann P, Viwatwongkasem C, Biggeri A. Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator. Biostatistics 2002; 3: 445457.
  • 34
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses BMJ 2003; 327: 557560.
  • 35
    Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e134.
  • 36
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
  • 37
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629634.
  • 38
    Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 39
    Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 12891298.
  • 40
    Martin A, Bloch M, Amin J et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009; 49: 15911601.
  • 41
    Cruciani M, Zanichelli V, Serpelloni G et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25: 19932004.
  • 42
    Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997; 126: 376380.